| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | APRE | Common Stock | Options Exercise | $25,300 | +27,500 | +160% | $0.9200* | 44,667 | 01 Oct 2021 | Direct | |
| transaction | APRE | Common Stock | Sale | $134,475 | -27,500 | -62% | $4.89 | 17,167 | 01 Oct 2021 | Direct | F1, F2 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | APRE | Stock Option (right to Buy) | Options Exercise | $0 | -27,500 | -52% | $0.000000 | 25,245 | 01 Oct 2021 | Common Stock | 27,500 | $0.9200 | Direct | F3 |
| Id | Content |
|---|---|
| F1 | The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. |
| F2 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.80 to $5.06 inclusive. The reporting person undertakes to provide Aprea Therapeutics, Inc., any security holder of Aprea Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F3 | This option was granted on September 14, 2016 and is fully exercisable. |